Sponsored by Oncology Nursing Society Foundation
4/1/2009 - 4/1/2011
Peripheral neuropathy is a painful and dose-limiting side effect of taxanes, commonly used chemotherapies to treat solid tumor and lymphoid cancers. For the purposes of this study, the taxane paclitaxel is proposed as the vehicle to initiate peripheral neuropathy. Known to occur in as many as 92% of all paclitaxel recipients, this painful neuropathy can reduce quality of life as a consequence of its adverse effects on functioning and ability to perform activities of daily living.
This study employs a 2x2x2 factorial design to determine the roles of sex, HPA axis responsivity, and paclitaxel on sleep architecture changes due to paclitaxel-induced neuropathic pain.